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Background: IMAgINE 1 assessed 52-week efﬁcacy and safety of adalimumab in children with moderate to severe Crohn’s disease. Long-term
efﬁcacy and safety of adalimumab for patients who entered the IMAgINE 2 extension are reported.
Methods: Patients who completed IMAgINE 1 could enroll in IMAgINE 2. Endpoints assessed from weeks 0 to 240 of IMAgINE 2 were Pediatric
Crohn’s Disease Activity Index remission (Pediatric Crohn’s Disease Activity Index # 10) and response (Pediatric Crohn’s Disease Activity Index
decrease $15 from IMAgINE 1 baseline) using observed analysis and hybrid nonresponder imputation (hNRI). For hNRI, discontinued patients were
imputed as failures unless they transitioned to commercial adalimumab (with study site closure) or adult care, where last observation was carried forward.
Corticosteroid-free remission in patients receiving corticosteroids at IMAgINE 1 baseline, discontinuation of immunomodulators (IMMs) in patients
receiving IMMs at IMAgINE 2 baseline, and linear growth improvement were reported as observed. Adverse events were assessed for patients receiving
$1 adalimumab dose in IMAgINE 1 and 2 through January 2015.
Results: Of 100 patients enrolled in IMAgINE 2, 41% and 48% achieved remission and response (hNRI) at IMAgINE 2 week 240. Remission rates
were maintained by 45% (30/67, hNRI) of patients who entered IMAgINE 2 in remission. At IMAgINE 2 week 240, 63% (12/19) of patients receiving
corticosteroids at IMAgINE 1 baseline achieved corticosteroid-free remission and 30% (6/20) of patients receiving IMMs at IMAgINE 2 baseline
discontinued IMMs. Adalimumab treatment led to growth velocity normalization. No new safety signals were identiﬁed.
Conclusions: Efﬁcacy and safety proﬁles of prolonged adalimumab treatment in children with Crohn’s disease were consistent with IMAgINE 1 and
adult Crohn’s disease adalimumab trials.
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C rohn’s disease (CD) is a progressive inﬂammatory disorderof the gastrointestinal tract. The incidence of CD is increas-
ing worldwide, with 15% to 25% of inﬂammatory bowel disease
cases manifesting in children and adolescents.1–3 Common com-
plications of pediatric CD include growth retardation, undernutri-
tion, and reduced health-related quality of life.4,5 Conventional
therapies for treatment of children with CD include corticoste-
roids and immunomodulators (IMMs).6,7 However, a substantial
number of cases are refractory to conventional therapy, and the
use of these therapies has been associated with growth impair-
ment,8,9 lymphoma, and nonmelanoma skin cancer.10–14
Adalimumab, a fully human monoclonal antibody, is
approved for use in children aged 6 to 17 years with moderately
to severely active CD (United States and Europe) and adolescents
aged 13 to 17 years weighing $40 kg with severely active CD
(Canada). The IMAgINE 1 trial was a 52-week, multicenter, ran-
domized, double-blind phase 3 study of adalimumab for moder-
ately to severely active pediatric CD. The results demonstrated
that adalimumab was an effective treatment for inducing and
maintaining clinical remission and response in this population,
with a safety proﬁle similar to that observed in adult CD trials.15
Children with moderately to severely active CD who
completed the IMAgINE 1 trial through week 52 and who had
responded any time were eligible to enter the open-label extension
IMAgINE 2 study. We present the long-term efﬁcacy and safety
of adalimumab treatment for more than 5 years in pediatric
patients with CD who enrolled in the IMAgINE 2 study.
MATERIALS AND METHODS
Patients and Study Design
The open-label extension study, IMAgINE 2 (Clinical-
Trials.gov identiﬁer, NCT00686374), has been conducted at 31
sites in Canada, Europe, and the United States since May 2008.
The current analysis was based on data collected through January
31, 2015, when the study was ongoing. By design, conduct of
IMAgINE 2 was to conclude at the time of adalimumab approval
and reimbursement for pediatric CD in each individual country.
Therefore, the duration of follow-up for an individual patient
varied depending on the location of the study site and the timing
of enrollment into IMAgINE 1. The study evaluated the long-term
maintenance of clinical efﬁcacy and safety of adalimumab treat-
ment in pediatric patients with CD who completed IMAgINE 1.
Eligible patients were those who successfully completed IMAgINE 1
through week 52 and achieved clinical response at any time
point during the study. The details of the IMAgINE 1 study
(ClinicalTrials.gov identiﬁer, NCT00409682) have been pub-
lished previously.15
The week 52 visit of IMAgINE 1 was the baseline visit for
IMAgINE 2. Patients who entered the open-label extension from
blinded (every other week [EOW] or every week [EW]) dosing in
IMAgINE 1 (low dose: 20 mg adalimumab if $40 kg or 10 mg
adalimumab if ,40 kg; high dose [HD]: 40 mg adalimumab if
$40 kg or 20 mg adalimumab if,40 kg) received open-label HD
EOW adalimumab based on body weight at that visit (40 mg
EOW adalimumab if $40 kg or 20 mg EOW adalimumab if
,40 kg). Patients who entered the open-label extension from
blinded EW dosing were changed to EOW dosing at that time
point per protocol. Patients who entered IMAgINE 2 from open-
label EW therapy in IMAgINE 1 (40 mg EW adalimumab if $40
kg or 20 mg EW adalimumab if ,40 kg) continued to receive the
same dose and frequency in IMAgINE 2.
Beginning at week 8 of IMAgINE 2, patients who
experienced disease ﬂares could move from open-label EOW
treatment to weekly treatment, continuing with the same dose of
adalimumab. Disease ﬂare was deﬁned as an increase in Pediatric
Crohn’s Disease Activity Index (PCDAI) of $15 points when
compared with the PCDAI obtained at the previous study visit.
Patients receiving weekly therapy could be discontinued from the
study at the investigator’s discretion if they developed a disease
ﬂare or PCDAI $15 points compared with baseline at any time
during the study.
CD-related concomitant medications could not be adjusted
during the ﬁrst 8 weeks of the study except for safety reasons.
After week 8 of IMAgINE 2, concomitant therapies could be
reduced or discontinued at the investigator’s discretion. Con-
versely, CD-related therapies could be initiated or reinitiated after
week 8, with the exception of IMM, which could not be rein-
stated. Corticosteroid tapering continued without interruptions for
patients who began their tapering in IMAgINE 1. At week 8,
patients who were not experiencing disease ﬂares could begin
corticosteroid tapering and corticosteroid doses could be
increased or reinitiated if a patient experienced a disease ﬂare.
Medications and therapies that were prohibited during the study
included live vaccines, concurrent biological therapies, growth
hormone, cyclosporine, and tacrolimus. Physical examination,
PCDAI, and sample collection for laboratory tests were obtained
at each visit.
Data Analysis
For this analysis, the long-term efﬁcacy and safety of
adalimumab were assessed up to January 31, 2015. Efﬁcacy was
assessed from weeks 0 to 240 of IMAgINE 2 (the latest visit that
all patients could have reached by the data cutoff date) in all
patients who entered IMAgINE 2 (N ¼ 100). Adverse event (AE)
rates were reported for any patient who entered IMAgINE 1 (N ¼
192) from the ﬁrst dose through the cutoff date of January 31,
2015, or up to 70 days after the last dose of adalimumab.
Efﬁcacy Assessments
Rates of clinical remission (PCDAI # 10), clinical response
(PCDAI decrease $15 points from IMAgINE 1 baseline), and
mean PCDAI were assessed over time. Subgroup analyses of
remission and response rates by previous inﬂiximab use were per-
formed. Discontinuation of corticosteroids and corticosteroid-free
remission (PCDAI # 10 and discontinued corticosteroid use) dur-
ing IMAgINE 2 were assessed in patients who used corticosteroids
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at IMAgINE 1 baseline and entered IMAgINE 2 (n ¼ 37). Discon-
tinuation of IMM use during IMAgINE 2 was assessed in patients
who received IMMs at IMAgINE 2 baseline (n ¼ 44).
Linear growth velocity was assessed by sex-speciﬁc height
velocity z score standardized by bone age, which was determined
using the Greulich and Pyle method for reading x-rays.16
Observed height velocity z scores were calculated for each patient
with reference to standard height velocity tables17 as previously
described.15 Linear growth analysis was limited to patients with
growth potential (female patients with bone age#13 yrs and male
patients with bone age #14 yrs) based on reports about median
bone age at puberty.18 Linear growth was assessed over time in
patients with linear growth impairment (height velocity z scores
# 21.0) at IMAgINE 1 baseline.
Health-related quality of life was assessed at study visits in
patients aged $10 years at IMAgINE 2 baseline using the
IMPACT III questionnaire, which was developed to assess quality
of life in pediatric patients with inﬂammatory bowel disease.19
IMPACT III contains 33 questions encompassing concerns in 6
domains: bowel, systemic function, emotional and social function,
body image, and treatments or tests. Scores range from 35 to 175,
and higher IMPACT III scores indicate a better quality of life.19
Safety Assessments
AEs, physical examination, vital signs, and laboratory data
were evaluated throughout the study. Treatment-emergent AEs
that occurred on or after the ﬁrst adalimumab dose and up to 70
days after the last dose or until the cutoff date (January 31, 2015)
were considered for this report. Safety data were collected at
regular intervals and by spontaneous reporting throughout
IMAgINE 1 and during the ongoing IMAgINE 2 trial. Patients
who completed (or early terminated) the study were contacted 70
days after their last dose of adalimumab to obtain information on
any ongoing or new AEs. AEs were summarized using the
Medical Dictionary for Regulatory Activities, version 13.1. Rates
of AEs of interest were assessed per 100 patient-years (PYs) of
exposure.
Statistical Analyses
Not all patients had the same duration of follow-up because
of different timing of enrollment into IMAgINE 1, country-
speciﬁc adalimumab approval, and study site shut down.
Consequently, rates of remission and response over time and
maintenance of remission and response were reported as observed
and analyzed using a hybrid nonresponder imputation (hNRI)
method. Patients with missing data or who discontinued from the
study for reasons other than study site closure or moving to adult
care were imputed using NRI. Patients who discontinued from the
study because of a study site closure and a documented change to
commercial adalimumab (n ¼ 18) or a move to adult treatment
(n ¼ 5) were imputed using last observation carried forward. For
last-observation-carried-forward analysis, the patient’s last non-
missing value after baseline was carried forward. Patients who
escalated to weekly dosing were not imputed as nonresponders.
Corticosteroid-free remission, discontinuation of corticosteroid
use, discontinuation of IMM use, mean PCDAI, median height
velocity z scores, and mean IMPACT III scores were reported as
observed. For IMPACT III scores, P values were calculated based
on a paired t-test.
Ethical Considerations
The IMAgINE 2 study protocol was approved by an
independent ethics committee or an institutional review board at
each site, and the study is being conducted in accordance with the
International Conference on Harmonisation guidelines, appropri-
ate regulations and guidelines governing clinical trial conduct,
and the ethical principles originating in the Declaration of
Helsinki. The parents/legal guardians of all participating patients
provided verbal or written informed consent.
RESULTS
Patient Disposition, Demographics, and
Baseline Characteristics
Of 192 patients who enrolled in IMAgINE 1, more than
half (N ¼ 100) entered IMAgINE 2. The disposition of patients
who enrolled in IMAgINE 1 and those who later entered
IMAgINE 2 is shown in Figure 1. During IMAgINE 2, 38 patients
escalated to weekly dosing (Fig. 1). As of the data cutoff on
January 31, 2015, there were 46 (46%) patients with efﬁcacy
endpoints at week 240 of IMAgINE 2 and 28 (28%) patients were
ongoing in the study. A total of 72 patients have discontinued
from IMAgINE 2 (Fig. 1). Lack of efﬁcacy (n ¼ 22) and AEs
(n ¼ 19) were the most frequent reasons for discontinuation.
Other reasons for discontinuation included (but were not limited
to) patients who transitioned to adult care (n ¼ 5) or discontinued
because adalimumab became commercially available in their
country (n ¼ 18).
Patient characteristics at IMAgINE 2 baseline for the 100
patients who entered the open-label extension are shown in
Table 1. Patient characteristics at IMAgINE 1 baseline for the
patients who entered IMAgINE 2 are also shown in Table 1 for
reference. On entry to IMAgINE 2, mean age was 14.5 years,
mean disease duration was 3.7 years, and median PCDAI was
7.5. A lower proportion of patients were using concomitant IMMs
at IMAgINE 2 baseline than at IMAgINE 1 baseline (44% versus
73%, respectively). A similar reduction in use of corticosteroids
was noted at IMAgINE 2 baseline (8%) versus IMAgINE 1
baseline (37%).
Long-term Efﬁcacy Outcomes
At week 240 of IMAgINE 2, remission and response were
achieved by 41% and 48% of patients who entered IMAgINE 2
(N ¼ 100) per hNRI analysis, respectively (Fig. 2A, B). At
IMAgINE 2 baseline, 67% of the 100 patients who entered the
study were in remission and 95% had achieved response. Of the
patients who entered IMAgINE 2 in remission, 45% (30/67, hNRI)
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maintained remission (Fig. 2C) and 50% (47/95, hNRI) of
patients who entered IMAgINE 2 with response maintained their
response at week 240, respectively (Fig. 2D). Remission and
response rates remained stable over time regardless of previous
inﬂiximab use (see Fig. 1, Supplemental Digital Content 1, http://
links.lww.com/IBD/B445).
Mean PCDAI for patients who entered IMAgINE 2 was
reduced from 40.1 at IMAgINE 1 baseline to 10.2 at IMAgINE 2
baseline after 52 weeks of adalimumab treatment, and reductions
were sustained through week 240 of IMAgINE 2 (mean PCDAI,
6.5, observed analysis; Fig. 2, Supplemental Digital Content 2,
http://links.lww.com/IBD/B446).
Corticosteroid-free remission rates in IMAgINE 2 among
patients who used corticosteroids at IMAgINE 1 baseline
increased from 40.5% (15/37) at enrollment into IMAgINE 2 to
63.2% (12/19, observed analysis) at week 240 of IMAgINE 2.
Discontinuation of corticosteroid use increased from week 12
(86.5% [32/37]) through week 240 of IMAgINE 2 (100% [19/19],
observed analysis). Discontinuation of IMM use among patients
who received IMMs at IMAgINE 2 baseline increased over time
from week 12 of IMAgINE 2 (2.4% [1/41]) through week 240
(30% [6/20], observed analysis) of IMAgINE 2.
Clinical Outcomes in Patients Who Dose De-
escalated at IMAgINE 2 Enrollment
Fifteen patients were receiving blinded HD weekly adali-
mumab at the end of IMAgINE 1 and, per protocol, de-escalated
the frequency of adalimumab to HD EOW when entering
IMAgINE 2. At week 240, remission and response rates for
patients who dose de-escalated were 20% (3/15, hNRI) and 33%
(5/15, hNRI), respectively.
Linear Growth Outcomes
Of the patients who entered IMAgINE 2, 58 patients had
linear growth impairment at IMAgINE 1 baseline (median height
velocity z score, 22.81 [range, 27.4 to 21.1]). Patients with
linear growth retardation at IMAgINE 1 baseline sustained im-
provements in growth velocity during IMAgINE 2. Median height
velocity z scores improved from the IMAgINE 1 baseline to 1.7
(range, 24.7 to 21.3; n ¼ 33) at IMAgINE 2 baseline and to 0.85
(range, 27.6 to 9.6; n ¼ 48) at week 48 of IMAgINE 2; as
expected, after initial increase, the growth rate approached the
median height velocity of the unaffected reference population
over time and normalization of growth velocity was sustained
through week 192 of IMAgINE 2 (median height velocity z score,
0 [range, 22.6 to 14.2]; n ¼ 16; observed analysis).
Health-related Quality of Life
At IMAgINE 1 baseline, mean 6 SD IMPACT III score
was 116.9 6 16.7 (n ¼ 96) for patients who entered IMAgINE 2,
indicating substantial impairment in quality of life before ada-
limumab treatment. Among these patients, mean 6 SD
IMPACT III score improved to 146.3 6 12.3 (n ¼ 58, P ,
0.001) at week 52 of IMAgINE 1 (i.e., IMAgINE 2 baseline)
FIGURE 1. Flow diagram. Patient enrollment in the IMAgINE 1 and 2 studies as of January 31, 2015, data cutoff. ADA, adalimumab. aPatients may
have had more than one reason for discontinuation.
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and maintenance adalimumab treatment sustained improve-
ments in IMPACT III scores through week 240 of IMAgINE 2
(mean 6 SD IMPACT III score, 144.1 6 18.7; n ¼ 45; P ,
0.001; observed analysis; Fig. 3).
Safety
As of January 31, 2015, a total of 192 pediatric patients
received$1 dose of adalimumab in IMAgINE 1 and IMAgINE 2,
representing 498.1 PY of exposure. The mean duration of expo-
sure was 4.5 years, and 25% of patients were followed for a total
of 286 weeks (i.e., 5.5 yrs including exposure in IMAgINE 1 and
IMAgINE 2; Fig. 3, Supplemental Digital Content 3, http://links.
lww.com/IBD/B447). Exposure-adjusted rates of treatment-
emergent AEs of interest in all patients treated with adalimumab
during the entire treatment period were similar to or lower than
those observed during IMAgINE 1 (Table 2). Serious AEs (n ¼
92, 48%) and AEs leading to discontinuation (n ¼ 61, 32%) of
study drug were primarily due to worsening or ﬂare of CD. The
most frequently reported AEs were CD (n ¼ 105, 55%), headache
(n ¼ 51, 27%), upper respiratory tract infection (n ¼ 43, 22%),
nasopharyngitis (n ¼ 40, 21%), and diarrhea (n ¼ 37, 19%). Most
infectious AEs were nonserious and not related to treatment (Sup-
plemental Table 1, Supplemental Digital Content 4, http://links.
lww.com/IBD/B448). All opportunistic infections were also con-
sidered nonserious (oral candidiasis, n¼ 7; Aeromona infection, n
¼ 1; fungal esophagitis, n¼ 1; and esophageal candidiasis, n¼ 1)
with the exception of disseminated histoplasmosis (n ¼ 1). The
most common hematologic AE reported was anemia (22 events),
and one event of noninfectious hepatitis was reported during the
open-label extension phase. No deaths, demyelinating disease,
malignancies, or active tuberculosis have been reported through-
out the treatment period.
For patients whose adalimumab dosage was increased
during IMAgINE 1 or IMAgINE 2 (n ¼ 121), exposure-
adjusted AE rates through the analysis cutoff date were similar
or lower after dose escalation compared with AE rates before
receiving the escalated dose (see Table 2, Supplemental Digital
Content 5, http://links.lww.com/IBD/B449), indicating that in this
limited sample size dosage adjustment did not affect AE rates.
Patients receiving concomitant corticosteroids (n¼ 72) at IMAgINE 1
baseline experienced more serious AEs (43.3 events/100 PYs)
than patients not receiving corticosteroids (n ¼ 120; 26.6
events/100 PY; P ¼ 0.002 by Poisson regression).
DISCUSSION
In the IMAgINE 1 study,15 adalimumab was shown to be
effective for inducing and maintaining clinical remission and
response in children with moderately to severely active CD who
had failed conventional therapies or previous anti–tumor necrosis
factor therapy. The long-term efﬁcacy and safety proﬁle of adali-
mumab in this patient population has not been previously reported
beyond 52 weeks. In this analysis of patients who entered the
ongoing open-label extension, IMAgINE 2, the long-term efﬁcacy
and safety of adalimumab in children with CD were assessed
based on more than 5 years of exposure. Our ﬁndings showed
that the clinical remission and response rates that were achieved
with 1 year of adalimumab therapy in IMAgINE 1 were main-
tained in about half the patients at week 240 of IMAgINE 2. In
TABLE 1. Demographics and Characteristics at
Baseline of IMAgINE 1 and 2 for Patients Who Entered
IMAgINE 2
Characteristic
IMAgINE 1
BL,
N ¼ 100
IMAgINE 2
BL,
N ¼ 100
Male, n (%) 52 (52.0)
Race, white, n (%) 93 (93.0)
Age, yr, mean (SD) 13.5 (2.5) 14.5 (2.4)
Weight, kg, mean (SD) 43.8 (14.3) 49.1 (14.5)
Height, cm, mean (SD) 153.2 (14.3) 157.9 (13.1)
Height velocity z score,
median (range)
20.58 (27.3 to
16.1)
0 (24.6 to 21.3)
CRP, mg/dL, median (range) 1.14 (0 to 14.4)a 0.14 (0 to 11.1)
Albumin, g/L, mean (SD) 40.4 (5.5) 42.4 (5.2)
ESR, mm/h, mean (SD) 32.4 (21.5)b 19.0 (15.7)
PCDAI, mean (median,
range)
40.1 (40.0, 25.0–62.5) 10.2 (7.5, 0–57.5)
Disease duration, yr, mean
(SD)
2.7 (2.1) 3.7 (2.1)
Involved intestinal area,c
n (%)
Colon 80 (80.0) ND
Ileum 85 (85.0) ND
Gastroduodenum 39 (39.0) ND
Rectum 41 (41.0) ND
Anal/perianal 33 (33.0) ND
Jejunum 8 (8.0) ND
Other 10 (10.0) ND
Draining ﬁstula(s), n (%) 23 (23.0) 8 (8.0)
Previous inﬂiximab use,
n (%)
29 (29.0)
Concomitant medication use
at BL, n (%)
Systemic corticosteroids 37 (37.0) 8 (8.0)
IMMs 73 (73.0) 44 (44.0)
IMMs and corticosteroids 22 (22.0) 5 (5.0)
Total IMPACT III score,
mean (SD)
116.87 (16.72) 141.0 (16.1)d
BL in IMAgINE 2 is deﬁned as the last nonmissing value on or before the ﬁrst dose date
of IMAgINE 2.
an ¼ 98.
bn ¼ 97.
cPatients could have multiple CD locations.
dn ¼ 99.
BL, baseline; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ND, not
determined.
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addition, normalization of linear growth velocity and improve-
ments in health-related quality of life that were achieved with 1
year of adalimumab therapy in IMAgINE 1 were maintained for
up to another 4.5 years during IMAgINE 2.
We also demonstrated that .80% of patients were able
to discontinue use of corticosteroids, and corticosteroid-free
remission was achieved and sustained in .60% of patients receiv-
ing long-term adalimumab treatment up to week 240 of IMAgINE
2. These ﬁndings are of particular importance in children and ado-
lescents because prolonged exposure to corticosteroids increases
the risk of infection in children with inﬂammatory bowel disease,20
resulting in growth suppression21 and patients falling short of their
target height as adults.22 Consequently, corticosteroid-free remis-
sion is a major therapeutic goal for children with CD based on
current treatment guidelines.23 Furthermore, discontinuation of
concomitant IMM, which was at the discretion of investigators,
increased over time, possibly reﬂecting the increased awareness
of the risk of lymphoma with IMMs.10,12,20
Results in patients who received weekly HD adalimumab at
the end of IMAgINE 1 and de-escalated to EOW HD when
entering IMAgINE 2 suggest that the dosing interval may be
reduced to EOW in some patients who received weekly
adalimumab; however, the overall number of patients was small,
and results should be interpreted with caution.
Based on current guidelines, one of the treatment goals for
pediatric patients with CD, in addition to symptom relief, is
improvement of growth outcomes. Linear growth retardation is
one of the most common complications of pediatric CD, and
approximately one-third of children and adolescents with CD
experience growth failure.24,25 Results of the IMAgINE 1 study
showed that adalimumab treatment signiﬁcantly improved linear
growth rate in children with CD, indicated by an increase in
FIGURE 3. Mean IMPACT III score over time in patients who entered
IMAgINE 2. Results at IMAgINE 1 baseline for patients who entered
IMAgINE 2 are shown for reference, as observed analysis. BL, baseline.
FIGURE 2. Long-term clinical remission and response rates with adalimumab treatment in patients who entered IMAgINE 2 (N ¼ 100). A, Pro-
portion of patients in remission over time. B, Proportion of patients with response over time. C, Proportion of patients in remission over time who
entered IMAgINE 2 in remission (n ¼ 67). D, Proportion of patients with response over time who entered IMAgINE 2 with response (n ¼ 95).
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height velocity z scores at weeks 26 and 52.15 In this analysis, we
assessed the long-term effect of adalimumab on growth outcomes
in a selected population of patients who exhibited linear growth
impairment but still had physiologic growth potential as assessed
by bone age. Our ﬁndings showed that long-term adalimumab
treatment achieved and sustained normal linear growth rates in
patients with growth retardation at IMAgINE 1 baseline, demon-
strating that long-term adalimumab therapy may address signiﬁ-
cant disease complications beyond mere symptom control.
Furthermore, sustained improvements in IMPACT III scores
through week 240 of IMAgINE 2 also suggest that adalimumab
therapy has favorable effects on health-related quality of life,
another important treatment goal for pediatric patients with CD.23
The safety proﬁle of long-term adalimumab therapy in
pediatric patients with CD is consistent with AE rates reported in
other adult and pediatric CD trials15,26 and with the overall safety
proﬁle of adalimumab in multiple indications spanning over 12
years of experience.27 We identiﬁed no new safety signals with
long-term adalimumab exposure, including all patients who
received adalimumab in IMAgINE 1 and IMAgINE 2. No malig-
nancies were reported, and AE rates remained stable or decreased
over time. Furthermore, dose escalation to weekly dosing did not
affect AE rates.
This is the ﬁrst prospective multicenter trial of the long-term
efﬁcacy and safety of adalimumab in children with CD; however,
this study is not without limitations. Because of the long-term
open-label clinical study design, there was a loss of patient data
over time after discontinuation for several reasons, including lack
of efﬁcacy, AEs, the commercial availability of adalimumab, or
the transition to adult models of care. In addition, the sample size
has likely been too small to capture potential rare events.
Furthermore, as the study case report forms did not speciﬁcally
query if patients discontinued due to a move to commercial
adalimumab or a move to adult care and, in many cases, lacked
documentation of the reason for discontinuation, it is possible that
the hNRI method underestimated efﬁcacy at the later time points.
Per study protocol, patient selection was restricted because eligible
patients who enrolled in IMAgINE 2 were required to have
successfully completed IMAgINE 1 and achieved a clinical
response at any time point during IMAgINE 1. Also, dose
adjustment based on therapeutic drug monitoring was not a part
of this long-term study. Finally, the IMAgINE 1 and 2 trials did
not assess mucosal healing in pediatric patients with CD receiving
adalimumab. Achievement of mucosal healing and clinical
remission (deep remission) is gaining increasing interest and has
emerged as a treatment goal in adult and pediatric CD trials.28,29
In conclusion, these results demonstrate that long-term
adalimumab treatment is beneﬁcial for pediatric patients with
moderately to severely active CD who have failed conventional
therapies and previous anti–tumor necrosis factor therapy. Our
ﬁndings are consistent with previously published adalimumab
studies in multiple indications26,27,30,31 and show that efﬁcacy
and safety of long-term adalimumab treatment remained stable
for more than 5 years in a pediatric CD population.
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